Science1 publisher2 min readPublished
Ben-Gurion researchers trace a redox switch that tips stressed human cells into apoptosis
Ben-Gurion University researchers say disulfide bonds in two ER chaperones, DNAJB12 and DNAJB14, decide whether stressed human cells survive or self-destruct. The evidence comes from cultured human cell lines, so using the pair against chemotherapy-resistant tumours is still a hypothesis to test.
The Scientist · Science desk
What happened
- A Ben-Gurion University team reports in Redox Biology a molecular switch that decides whether stressed human cells turn on a survival route or undergo apoptosis.
- Under moderate stress, disulfide bonds keep the chaperones DNAJB12 and DNAJB14 working, moving ER proteins to the cytosol and sending pro-apoptotic proteins to the proteasome.
- Under overwhelming stress, rising glutathione breaks those bonds, and the cell rapidly degrades both chaperones.
- The death protein BIK then builds up and recruits BAX and BAK, which permeabilise the ER membrane and commit the cell irreversibly to apoptosis.
- The findings come from pharmacological and physiological stress models run across multiple human cell lines.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint Because the switch has been shown only in cultured human cells, the promised benefit against chemotherapy resistance cannot yet be sized or compared with other strategies.
- exposure A treatment that disables DNAJB12 and DNAJB14 body-wide would push heart muscle toward the same cell death the cardiac work hopes to prevent, so tumour selectivity becomes a design requirement.
- capability Chemoresistance research now has two named proteins and a specific chemical state, intact disulfide bonds, to look for in resistant tumours.
The death signal in this account comes from an antioxidant. Rising glutathione is what breaks the chaperones' disulfide bonds and sets off their destruction [8]. The team treats that bond chemistry as a sensor. "Our findings demonstrate that the cell's internal redox balance functions as a definitive molecular scale," said Aeid Igbaria, who led the study [10][2]. "Instead of a passive structural breakdown, the cell actively measures stress levels through the integrity of these chemical bonds." [10]
According to the BGU account, cancer cells often hijack ER-to-cytosol signalling, or ERCYS, to survive harsh microenvironments and resist drugs [4]. When the route runs, and why it shuts down under extreme stress, had remained unclear [4]. Proteins that escape the ER this way block tumour suppressors and deactivate death enzymes such as caspase-3 [3]. The new work confines the route to a stress window set by the cell's redox balance [6]. The paper's title describes the ER protein reflux as "chaperone- and Bax/Bak-dependent" [13].
Experiments in cultured cells can put these steps in order under controlled stress. They cannot show that a tumour in a patient sits inside the survival window, or that pushing it out would beat resistance to a particular drug. The phys.org account does not name the cell lines, give the size of the shift in cell death, or describe any animal or drug-treatment test [5].
The therapeutic case is built across that gap. "Because cancer cells rely heavily on this chaperone-assisted pathway to resist chemotherapy, disrupting DNAJB12 and DNAJB14 or altering the ER redox environment could strip tumor cells of their defenses and force them into apoptosis," said Laila Abu Madegam, a co-lead author [11][2].
The team also verified the cascade in cardiac models of hypoxia-reoxygenation. It suggests that modulating the switch could protect heart muscle from mass cell death after ischemic injury [12]. Protecting the heart would mean keeping the chaperones intact, while the cancer proposal means disabling them [11][12]. I'd expect any cancer drug aimed at DNAJB12 and DNAJB14 to need a way of reaching tumour cells while sparing heart muscle, since the same cascade has been shown to run in cardiac models [12].
What to watch
- Whether disrupting DNAJB12/14 or shifting ER redox state restores drug sensitivity in chemotherapy-resistant tumour models or animals, with a measured effect on response.
- Whether chaperone bond status or glutathione levels differ between chemotherapy-resistant and chemotherapy-sensitive tumours in patient samples.
- Whether the hypoxia-reoxygenation result holds in animal models of ischemic heart injury.